Seikagaku BioBusiness

Seikagaku Corporation is a leading Japanese pharmaceutical company specializing in glycoscience, with a focus on developing and manufacturing products derived from hyaluronic acid and other glycosaminoglycans. The company operates through two primary segments: Pharmaceuticals, which includes joint function improvement agents and ophthalmic surgical aids, and the LAL business (formerly Seikagaku BioBusiness), which provides endotoxin-detecting reagents for pharmaceutical quality control. Seikagaku follows a unique business model, concentrating its resources on R&D and manufacturing while partnering with global pharmaceutical leaders for sales and distribution. Its key products include ARTZ/SUPARTZ and Gel-One for osteoarthritis, and HERNICORE for lumbar disc herniation, with a robust pipeline utilizing proprietary glycosaminoglycan modification and cross-linking technologies.